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Introduction {#sec1}
============

Venetoclax is an oral BCL2 inhibitor undergoing investigation for use in relapsed or refractory multiple myeloma (RRMM), particularly in combination with proteasome inhibitors (VPI)\[1,2\]. An interim analysis of a current phase 2 trial of venetoclax with carfilzomib in RRMM demonstrated an overall response rate of 78% with a very good partial response rate of 56%\[3,4\]. However, a separate ongoing phase 3 trial of venetoclax with bortezomib found a decrease in overall survival due to increased fatal infections in the venetoclax arm compared to placebo. Better describing these infections may give insight into the pathophysiology and prove useful in mitigating strategies for use with VPI therapy in RRMM.

Methods {#sec2}
=======

We retrospectively analyzed patients treated with VPI for infectious complications from initiation of treatment until one month after progression. Infections were classified by site, pathogen and severity of infection defined as requiring hospitalization. Additional data collected were regimen, demographics, cell counts, quantitative immunoglobulins, m-spike, cytogenetics, prior lines of therapy, prophylactic antibiotics and IVIG use.

Results {#sec3}
=======

18 patients treated with a VPI combination regimen were identified with 78% males. The median age was 64.5 (range 47-76) and a median of 3 prior regimens. 14 were treated with combination carfilzomib and 4 with bortezomib. 4 patients progressed by the time of data collection. 11 patients experienced 35 discrete infectious episodes resulting in 5 hospitalizations. Respiratory infections predominated (29/35) with 24 upper respiratory infections/sinusitis. 5 were lower respiratory infections and comprised all hospitalizations. Among respiratory infections, viruses were the only pathogens identified, including influenza, rhinovirus, coronavirus and RSV. Other sites of infection were gastrointestinal (including recurrent C. difficile) and urinary tract. No CNS, blood, or intra-abdominal infections were identified. A qualitative analysis of laboratory data revealed that ALC and non-monoclonal IgG levels rapidly declined and remained suppressed after initiation of VPI, while ANC remained nominal. No clear trends between severe infections and degree or hypogammaglobulinemia or lymphopenia were observed.

Conclusion {#sec4}
==========

Patients with RRMM treated with VPI experience frequent infectious complications, some severe, and sustained reductions in serum IgG and lymphopenia without neutropenia. Identified infectious pathogens tend toward viral infections for likely multifactorial reasons. These findings warrant continued investigation into mechanisms of immunocompromise and if a differential risk profile exists between proteasome inhibitors in this type of regimen. Additionally, these findings suggest that IVIG infusion may be a more biologically-logical strategy to infection prophylaxis compared to oral antibiotics and requires further research.

Keywords {#sec5}
========

hypogammaglobulinemia

Infections

Venetoclax

Tracks {#sec6}
======

Multiple Myeloma Novel Drug Targets
